Research programme: matrix metalloproteinase inhibitors - Shionogi

Drug Profile

Research programme: matrix metalloproteinase inhibitors - Shionogi

Alternative Names: MMI 116; MMI-166

Latest Information Update: 20 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shionogi
  • Class Sulfonamides
  • Mechanism of Action Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Osteoarthritis; Solid tumours

Most Recent Events

  • 31 Dec 2004 Preclinical trials in Osteoarthritis in Japan (unspecified route)
  • 16 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the Cancer pharmacodynamics section
  • 30 Oct 2002 Preclinical trials in Solid tumours in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top